National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Access to Care (1)
- Adverse Drug Events (ADE) (3)
- Adverse Events (1)
- (-) Cancer (19)
- Cancer: Colorectal Cancer (1)
- Cancer: Prostate Cancer (1)
- Care Management (1)
- Children/Adolescents (3)
- Chronic Conditions (1)
- Comparative Effectiveness (4)
- Elderly (4)
- Falls (1)
- Healthcare Costs (5)
- Health Insurance (1)
- Medicare (4)
- (-) Medication (19)
- Osteoporosis (1)
- Pain (1)
- Palliative Care (1)
- Patient-Centered Outcomes Research (5)
- Patient Safety (1)
- Prevention (1)
- Quality of Life (1)
- Racial and Ethnic Minorities (1)
- Research Methodologies (1)
- Risk (1)
- Surgery (1)
- Treatments (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 19 of 19 Research Studies DisplayedAdams AS, Madden JM, Zhang F
Effects of transitioning to Medicare Part D on access to drugs for medical conditions among dual enrollees with cancer.
This study evaluated the impact of transitioning from Medicaid to Medicare Part D drug coverage on the use of noncancer treatments among dual enrollees with cancer. Its findings suggest that the removal of drug caps under Part D had a modest impact on the treatment of hypercholesterolemia overall and may have reduced white-black gaps in the use of lipid-lowering and antidepressant therapies.
AHRQ-funded; HS018577.
Citation: Adams AS, Madden JM, Zhang F .
Effects of transitioning to Medicare Part D on access to drugs for medical conditions among dual enrollees with cancer.
Value Health 2017 Dec;20(10):1345-54. doi: 10.1016/j.jval.2017.05.023.
.
.
Keywords: Access to Care, Cancer, Medicare, Medication, Racial and Ethnic Minorities
Chen Y, Lairson DR, Chan W
Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a U.S. payer's perspective.
The researchers sought to determine the cost-effectiveness (measured as cost per life-year saved) of front-line novel agent-based therapy use among a cohort of elderly patients with multiple myeloma (MM) in a real-world setting. They concluded that, given the most common treatment practices in the United States, the use of novel agent-based therapy is not cost-effective at its current level of cost and effectiveness.
AHRQ-funded; HS018956.
Citation: Chen Y, Lairson DR, Chan W .
Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a U.S. payer's perspective.
J Manag Care Spec Pharm 2017 Aug;23(8):831-43. doi: 10.18553/jmcp.2017.23.8.831.
.
.
Keywords: Healthcare Costs, Cancer, Comparative Effectiveness, Healthcare Costs, Medication
Shih YT, Xu Y, Liu L
Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries.
This study examined trends in targeted oral anticancer medication (TOAM) prices and patient out-of-pocket (OOP) payments in Medicare Part D and estimated the actual effects on patient OOP payments of partial filling of the coverage gap by 2012. It concluded that rising TOAM prices threaten the financial relief patients have begun to experience under closure of the coverage gap in Medicare Part D.
AHRQ-funded; HS020263.
Citation: Shih YT, Xu Y, Liu L .
Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries.
J Clin Oncol 2017 Aug 1;35(22):2482-89. doi: 10.1200/jco.2017.72.3742.
.
.
Keywords: Cancer, Medication, Healthcare Costs, Medicare, Elderly
Lou I, Chennell TB, Schaefer SC
Optimizing outpatient pain management after thyroid and parathyroid surgery: a two-institution experience.
This study aimed to describe the outpatient narcotic medication needs for patients undergoing thyroid and parathyroid surgery, and to identify predictors of higher requirement. It concluded that overall, 93 percent of patients undergoing thyroidectomy and parathyroidectomy require 20 or fewer oral morphine equivalents by their postoperative visit.
AHRQ-funded; HS023009.
Citation: Lou I, Chennell TB, Schaefer SC .
Optimizing outpatient pain management after thyroid and parathyroid surgery: a two-institution experience.
Ann Surg Oncol 2017 Jul;24(7):1951-57. doi: 10.1245/s10434-017-5781-y.
.
.
Keywords: Cancer, Medication, Pain, Patient-Centered Outcomes Research, Surgery
Winters-Stone KM, Moe E, Graff JN
Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy.
This study compared the prevalence of and association between falls and frailty of prostate cancer survivors (PCSs) who were current, past or never users of androgen deprivation therapy (ADT). It concluded that current and past exposure to ADT is linked to higher risk of falls and frailty than no treatment.
AHRQ-funded; HS022981.
Citation: Winters-Stone KM, Moe E, Graff JN .
Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy.
J Am Geriatr Soc 2017 Jul;65(7):1414-19. doi: 10.1111/jgs.14795.
.
.
Keywords: Cancer: Prostate Cancer, Cancer, Falls, Medication, Elderly
Wilfond BS, Morales C, Taylor HA
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Many Phase I oncology trials include an eligibility criterion requiring potential participants to fail standard chemotherapy. The rationale for this approach is to ensure that patients do not forgo established clinical approaches. The case described in this report has the additional feature of the consultation being requested by a research participant who wanted to challenge the ethical rationale for such an eligibility criterion.
AHRQ-funded; HS000029.
Citation: Wilfond BS, Morales C, Taylor HA .
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Am J Bioeth 2017 Apr;17(4):66-67. doi: 10.1080/15265161.2017.1284934..
Keywords: Cancer, Treatments, Medication
Wilfond BS, Morales C, Taylor HA
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Many Phase I oncology trials include an eligibility criterion requiring potential participants to fail standard chemotherapy. The rationale for this approach is to ensure that patients do not forgo established clinical approaches. The case described in this report has the additional feature of the consultation being requested by a research participant who wanted to challenge the ethical rationale for such an eligibility criterion.
AHRQ-funded; HS000029.
Citation: Wilfond BS, Morales C, Taylor HA .
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Am J Bioeth 2017 Apr;17(4):66-67. doi: 10.1080/15265161.2017.1284934..
Keywords: Cancer, Treatments, Medication
Dorris K, Liu C, Li D
A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.
A systematic review of pediatric phase I solid tumor trials published in 1990-2013 was performed. The published reports were evaluated for patient characteristics, toxicity information, and response numbers. The review concluded that in phase I pediatric solid tumor trials, objective response rates were significantly higher for cytotoxic versus targeted agents. Stable disease rates were similar in targeted and cytotoxic drug trials.
AHRQ-funded; HS022437.
Citation: Dorris K, Liu C, Li D .
A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.
Pediatr Blood Cancer 2017 Mar;64(3). doi: 10.1002/pbc.26258.
.
.
Keywords: Patient Safety, Patient-Centered Outcomes Research, Children/Adolescents, Cancer, Medication
Shen C, Zhao B, Liu L
Financial burden for patients with chronic myeloid leukemia enrolled in Medicare Part D taking targeted oral anticancer medications.
In this study, the investigators examined financial burden for patients with chronic myeloid leukemia enrolled in Medicare Part D taking targeted oral anticancer medications. The authors concluded that patients experience quick entry and exit from the coverage gap (also called the donut hole) as a result of the high price of targeted oral anticancer medications. They suggested that closing the donut hole would provide financial relief during the initial month(s) of treatment but will not completely eliminate the financial burden.
AHRQ-funded; HS020263.
Citation: Shen C, Zhao B, Liu L .
Financial burden for patients with chronic myeloid leukemia enrolled in Medicare Part D taking targeted oral anticancer medications.
J Oncol Pract 2017 Feb;13(2):e152-e62. doi: 10.1200/JOP.2016.014639..
Keywords: Cancer, Chronic Conditions, Elderly, Healthcare Costs, Medicare, Medication
Wang WJ, Robertson JC, Basu A
Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.
This study explored whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI). It concluded that investments in trials were positively associated only with contemporary changes in BI (2008-2014). The relationship was stronger for government-sponsored comparative-effectiveness trials than for industry.
AHRQ-funded; HS022982.
Citation: Wang WJ, Robertson JC, Basu A .
Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.
J Comp Eff Res 2017 Jan;6(1):15-24. doi: 10.2217/cer-2016-0021.
.
.
Keywords: Cancer, Comparative Effectiveness, Medication, Research Methodologies
Arvold ND, Cefalu M, Wang Y
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
It is unknown whether the addition of temozolomide (TMZ) to radiotherapy (RT) is associated with improved overall survival among older glioblastoma patients. This study found that among a large cohort of older glioblastoma patients treated in a real-world setting, the addition of TMZ to RT was associated with a small survival gain.
AHRQ-funded; HS021991.
Citation: Arvold ND, Cefalu M, Wang Y .
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
J Neurooncol 2017 Jan;131(2):301-11. doi: 10.1007/s11060-016-2294-7.
.
.
Keywords: Cancer, Comparative Effectiveness, Elderly, Medication, Patient-Centered Outcomes Research
Goodwin JS, Zhou J, Kuo YF
Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer.
The researchers compared the risk of jaw osteonecrosis after intravenous (IV) bisphosphonate administered to patients with cancer vs patients without cancer. During follow-up, 40 (0.42 percent) out of 9,482 patients with cancer developed probable jaw osteonecrosis compared with 8 (0.05 percent) out of 16,046 patients without cancer.
AHRQ-funded; HS022134.
Citation: Goodwin JS, Zhou J, Kuo YF .
Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer.
Mayo Clin Proc 2017 Jan;92(1):106-13. doi: 10.1016/j.mayocp.2016.09.015.
.
.
Keywords: Cancer, Osteoporosis, Risk, Medication, Patient-Centered Outcomes Research
Hochman MJ, Kamal AH, Wolf SP
Anticholinergic drug burden in noncancer versus cancer patients near the end of life.
This article's objective is to determine anticholinergic load (ACL) and its impact in noncancer versus cancer palliative care patients. The authors concluded that ACL is associated with worse fatigue and quality of life and may not differ significantly between cancer and noncancer patients nearing end of life. Symptom management drugs are more responsible for ACL in cancer and noncancer patients, although disease management drugs contribute significantly to ACL in the latter group. They recommend more attention to reducing anticholinergic use in all patients with life-limiting illness.
AHRQ-funded; HS023681.
Citation: Hochman MJ, Kamal AH, Wolf SP .
Anticholinergic drug burden in noncancer versus cancer patients near the end of life.
J Pain Symptom Manage 2016 Nov;52(5):737-43.e3. doi: 10.1016/j.jpainsymman.2016.03.020.
.
.
Keywords: Adverse Drug Events (ADE), Cancer, Medication, Palliative Care, Quality of Life
Bennette CS, Richards C, Sullivan SD
Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure.
The researchers used pharmacy claims for commercially insured individuals to examine trends in postlaunch prices over time for orally administered anticancer drugs recently approved by the Food and Drug Administration. They found that in the period 2007-13, inflation-adjusted per patient monthly drug prices increased 5 percent each year.
AHRQ-funded; HS022982.
Citation: Bennette CS, Richards C, Sullivan SD .
Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure.
Health Aff 2016 May;35(5):805-12. doi: 10.1377/hlthaff.2015.1145.
.
.
Keywords: Cancer, Healthcare Costs, Medication
Thompson KD, Connor SJ, Walls DM
Patients with ulcerative colitis are more concerned about complications of their disease than side effects of medications.
The survey’s aim was to better understand what aspects of ulcerative colitis (UC) and UC management, are most concerning to patients, and how they would like to be informed about treatment options. It found that most patients (87 percent) wanted to share treatment decision making with their doctors. Patients were most concerned about the risk of colorectal cancer (37 percent), and the possible need for an ileostomy (29 percent).
AHRQ-funded; HS021747.
Citation: Thompson KD, Connor SJ, Walls DM .
Patients with ulcerative colitis are more concerned about complications of their disease than side effects of medications.
Inflamm Bowel Dis 2016 Apr;22(4):940-7. doi: 10.1097/mib.0000000000000740.
.
.
Keywords: Adverse Drug Events (ADE), Cancer, Cancer: Colorectal Cancer, Care Management, Medication
Freedman JL, Faerber JI, Kang TI
Predictors of antiemetic alteration in pediatric acute myeloid leukemia.
The purpose of this study was to gain better knowledge of patient and cancer treatment factors associated with nausea/vomiting (NV) in order to enhance prophylaxis in children being treated for acute myeloid leukemia (AML). It found that treatment-related NV, as evidenced by antiemetic alterations, is more prevalent with increasing age.
AHRQ-funded; HS018425
Citation: Freedman JL, Faerber JI, Kang TI .
Predictors of antiemetic alteration in pediatric acute myeloid leukemia.
Pediatr Blood Cancer. 2014 Oct;61(10):1798-805. doi: 10.1002/pbc.25108..
Keywords: Adverse Drug Events (ADE), Adverse Events, Cancer, Children/Adolescents, Medication, Prevention
Feudtner C, Freedman J, Kang T
Comparative effectiveness of senna to prevent problematic constipation in pediatric oncology patients receiving opioids: a multicenter study of clinically detailed administrative data.
The researcher investigated senna’s effectiveness, compared with other prophylactic oral bowel medications, in reducing opioid-induced constipation in pediatric cancer patients. They found that initiating senna therapy within two days of starting opioids, compared with initiating another oral bowel medication, was significantly associated with a lower risk of problematic constipation.
AHRQ-funded; HS018425.
Citation: Feudtner C, Freedman J, Kang T .
Comparative effectiveness of senna to prevent problematic constipation in pediatric oncology patients receiving opioids: a multicenter study of clinically detailed administrative data.
J Pain Symptom Manage 2014 Aug;48(2):272-80. doi: 10.1016/j.jpainsymman.2013.09.009..
Keywords: Cancer, Children/Adolescents, Comparative Effectiveness, Patient-Centered Outcomes Research, Medication
Smieliauskas F, Chien CR, Shen C
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.
The researchers’ objective was to perform the first comprehensive review of cost-effectiveness analyses of targeted oral anti-cancer medications (OAMs). They concluded that in over half of the treatment settings in which a targeted OAM was compared with treatment that was not a targeted OAM, targeted OAMs were considered cost-effective.
AHRQ-funded; HS018535.
Citation: Smieliauskas F, Chien CR, Shen C .
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.
Pharmacoeconomics 2014 Jul;32(7):651-80. doi: 10.1007/s40273-014-0160-z..
Keywords: Cancer, Healthcare Costs, Medication
Erten MZ, Davidoff AJ, Zuckerman IH
AHRQ Author: Davidoff AJ
The effect of supplemental medical and prescription drug coverage on health care spending for Medicare beneficiaries with cancer.
The researchers examined whether patients with newly diagnosed cancer respond differently to supplemental coverage than the general Medicare population. They concluded that Medicare beneficiaries with cancer are less responsive to the presence and type of supplemental insurance than are beneficiaries without cancer. They recommended that policymakers consider welfare effects associated with coverage restrictions.
AHRQ-authored.
Citation: Erten MZ, Davidoff AJ, Zuckerman IH .
The effect of supplemental medical and prescription drug coverage on health care spending for Medicare beneficiaries with cancer.
Value Health 2014 Jan-Feb;17(1):15-21. doi: 10.1016/j.jval.2013.11.003.
.
.
Keywords: Cancer, Health Insurance, Medicare, Medication